メタボリックシンドロームの世界市場（2023年版）：適応症別（NASH、IRS、高コレステロール血症、肥満症候群、その他）、分子タイプ別、投与経路別、地域別、国別の分析：市場インサイトと予測（2018年～2028年）

Global Metabolic Syndrome Market (2023 Edition): Analysis By Indication (NASH, IRS, Hypercholesterolemia, Obesity Syndrome, Others), By Molecule Type, Route of Administration, By Region, By Country: Market Insights and Forecast (2018-2028)

エグゼクティブサマリー Azoth Analytics社は、「メタボリックシンドローム市場（2023年版）」と題する調査レポートを発表し、世界のメタボリックシンドローム産業の市場細分化の観点から、「適応症別（インス... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2023年6月1日	US$2,400 シングルユーザライセンスライセンス・価格情報注文方法はこちら	270	英語

サマリー

エグゼクティブサマリー

Azoth Analytics社は、「メタボリックシンドローム市場（2023年版）」と題する調査レポートを発表し、世界のメタボリックシンドローム産業の市場細分化の観点から、「適応症別（インスリン抵抗性症候群、高コレステロール血症、肥満症候群、2018-2022年の過去期間、2023年の推定期間、2024-2028年の予測期間について、適応症別（非アルコール性脂肪肝炎、その他の適応症）、分子タイプ別（低分子、タンパク質、RNA/DNA、その他の分子）、投与経路別（経口、皮下、その他のROA）。

この調査研究はグローバルな性質を持ち、南北アメリカ（米国、カナダ、南北アメリカの残り）、ヨーロッパ（フランス、英国、イタリア、スペイン、ドイツ、ヨーロッパの残り）、アジア太平洋（中国、日本、インド、アジア太平洋の残り）、中東・アフリカの市場を詳細に分析するものである。さらに、この調査レポートは、市場規模、年間成長＆潜在能力分析、市場プレイヤーの競争力調査、投資機会、将来予測の需要などのデータを提示します。

また、市場成長指標、阻害要因、需給リスク、その他の重要な統計データ、市場の進化に関連する現在および将来の市場動向の完全評価も行っています。

メタボリックシンドロームの世界市場は、2021年の225億米ドルから2028年末までに289億米ドルを生み出すと予測されます。メタボリックシンドロームは、心血管疾患、2型糖尿病、およびその他の主要な健康問題のリスクを高める、連動した代謝異常のグループによって特徴付けられる複雑な疾患です。公衆衛生に大きな影響を与える世界的な健康問題です。中心性肥満、高血圧、脂質異常症（脂質プロファイルの異常）、グルコース代謝の低下は、メタボリックシンドロームの重要な構成要素です。予測期間である2024年から2028年にかけて、世界のメタボリックシンドローム市場はCAGR 46.30%で拡大すると予想されます。

また、ヘルスケア分野がより予防的でカスタマイズされたアプローチに移行するにつれ、メタボリックシンドロームに関連する課題のリスクを低減するために、早期発見と管理が重視されるようになってきています。このようなパターンは、診断検査、治療オプション、デジタルヘルスソリューションの需要を促進すると思われます。

企業は、メタボリックシンドロームの多くの側面に同時に対処する新薬の創出に取り組んでいます。この戦略では、複数の薬剤の必要性を減らしながら、患者の転帰を向上させることを目指します。さらに、ウェアラブルガジェットやモバイルアプリケーションなどの技術的進歩により、個人が自分の健康指標をモニタリングし、状態をうまく管理できるように進化しています。

適応症の種類のうち、インスリン抵抗性症候群が市場で最大のシェアを占めています。インスリン抵抗性メタボリックシンドロームの治療薬の世界市場は、糖尿病の有病率の増加により、今後数年間で成長すると予想されます。

また、本調査では、業界の競争状況や、ノボノルディスク、イーライリリー・アンド・カンパニー、武田薬品工業、サノフィ、アストラゼネカ、アムジェン、メルク社、ジョンソン＆ジョンソン、ファイザー、アボットなどのメタボリックシンドロームの世界市場における主要企業のプロファイルを提供します。企業プロフィールは、事業概要、医薬品の種類とその他の製品、主要な財務、最近のイベントと開発などの重要な情報を含んでいます。全体として、本レポートは世界のメタボリックシンドローム市場の詳細な概要を提供し、業界コンサルタント、機器メーカー、拡大機会を探している既存プレイヤー、機会を探している新規プレイヤー、その他の関係者が、市場中心の戦略を現在および将来の予想トレンドに合わせる際に役立つと思われます。

報告書の範囲

- 本レポートでは、メタボリックシンドローム市場を金額（USD Million）別に分析しています。

- 本レポートでは、メタボリックシンドローム市場の過去期間2018-2022年、推定期間2023年、予測期間2024-2028年の分析を紹介します。

- メタボリックシンドローム市場を適応症別（インスリン抵抗性症候群、高コレステロール血症、肥満症候群、非アルコール性脂肪肝炎、その他の適応症）に分析したレポートです。

- メタボリックシンドローム市場を分子タイプ（低分子、タンパク質、RNA/DNA、その他分子）別に分析したレポートです。

- メタボリックシンドローム市場を投与経路（経口、皮下、その他ROA）別に分析しています。

- メタボリックシンドロームの世界市場を、米国、カナダ、英国、ドイツ、フランス、イタリア、スペイン、中国、インド、日本などの国別に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析のフレームワークを通じて提示されています。また、市場の魅力は、地域別、メタボリックシンドロームタイプ別、メタボリックシンドローム形態別、販売チャネル別で提示されています。

- また、業界の主な機会、トレンド、ドライバー、課題についても分析されています。

- 競合他社の動向、戦略、M&A、新製品開発についても追跡しています。本レポートで分析した企業は、ノボノルディスク、イーライリリー・アンド・カンパニー、武田薬品工業、サノフィ、アストラゼネカ、アムジェン、メルク株式会社、ジョンソン＆ジョンソン、ファイザー、アボットです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

3. Global Metabolic Syndrome Market: Historic and Forecast (2018-2028)

3.1 Impact Analysis of Macro Economic Factors on Metabolic Syndrome Market

3.2 Impact of COVID-19 on Metabolic Syndrome Market

3.3 Global Metabolic Syndrome Market: Ecosystem Analysis

3.3.1 Metabolic Syndrome Fact Sheet

3.3.2 Pipeline Analysis of Metabolic Syndrome Therapeutics

3.3.3 Global Obesity Statistics 2022, in Millions

3.3.4 Top marketed Metabolic Syndrome Therapeutics by NPV, USDm

3.3.5 Top pipeline Metabolic Syndrome Therapeutics by NPV, in USD Millions

3.4 Global Metabolic Syndrome Market: Dashboard

3.5 Global Metabolic Syndrome Market: Market Value Assessment, 2018-2028 (USD Million)

3.6 Global Metabolic Syndrome Market Segmentation: By Indication

3.6.1 Global Metabolic Syndrome Market, By Indication Type Overview

3.6.2 Global Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

3.6.3 Global Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)

3.6.4 Global Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

3.6.5 Global Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)

3.6.6 Global Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)

3.7 Global Metabolic Syndrome Market Segmentation: By Molecule Type

3.7.1 Global Metabolic Syndrome Market, By Molecule Type Overview

3.7.2 Global Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)

3.7.3 Global Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)

3.7.4 Global Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)

3.7.5 Global Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)

3.8 Global Metabolic Syndrome Market Segmentation: By Route of Administration

3.8.1 Global Metabolic Syndrome Market, By Route of Administration Overview

3.8.2 Global Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

3.8.3 Global Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)

3.8.4 Global Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

4. Global Metabolic Syndrome Market, Region Analysis

4.1 Regional Coverage of the Study

5. Americas Metabolic Syndrome Market: Historic and Forecast (2018-2028)

5.1 Americas Metabolic Syndrome Market: Snapshot

5.2 Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.3 Americas Metabolic Syndrome Market: Key Factors

5.4 Americas Metabolic Syndrome Market Segmentation: By Indication

5.4.1 Americas Metabolic Syndrome Market, By Indication Overview

5.4.2 Americas Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

5.4.3 Americas Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)

5.4.4 Americas Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

5.4.5 Americas Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)

5.4.6 Americas Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)

5.5 Americas Metabolic Syndrome Market Segmentation: By Molecule Type

5.5.1 Americas Metabolic Syndrome Market, By Molecule Type Overview

5.5.2 Americas Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)

5.5.3 Americas Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)

5.5.4 Americas Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)

5.5.5 Americas Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)

5.6 Americas Metabolic Syndrome Market Segmentation: By Route of Administration

5.6.1 Americas Metabolic Syndrome Market, By Route of Administration Overview

5.6.2 Americas Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

5.6.3 Americas Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)

5.6.4 Americas Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

5.7 Americas Metabolic Syndrome Market Segmentation: By Country

5.7.1 United States Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.7.1.1 United States Metabolic Syndrome Market, By Indication

5.7.1.2 United States Metabolic Syndrome Market, By Molecule Type

5.7.1.3 United States Metabolic Syndrome Market, By Route of Administration

5.7.2 Canada Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.7.2.1 Canada Metabolic Syndrome Market, By Indication

5.7.2.2 Canada Metabolic Syndrome Market, By Molecule Type

5.7.2.3 Canada Metabolic Syndrome Market, By Route of Administration

5.7.3 Rest of Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.7.3.1 Rest of Americas Metabolic Syndrome Market, By Indication

5.7.3.2 Rest of Americas Metabolic Syndrome Market, By Molecule Type

5.7.3.3 Rest of Americas Metabolic Syndrome Market, By Route of Administration

6. Europe Metabolic Syndrome Market: Historic and Forecast (2018-2028)

6.1 Europe Metabolic Syndrome Market: Snapshot

6.2 Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.3 Europe Metabolic Syndrome Market: Key Factors

6.4 Europe Metabolic Syndrome Market Segmentation: By Indication

6.4.1 Europe Metabolic Syndrome Market, By Indication Overview

6.4.2 Europe Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

6.4.3 Europe Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)

6.4.4 Europe Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

6.4.5 Europe Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)

6.4.6 Europe Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)

6.5 Europe Metabolic Syndrome Market Segmentation: By Molecule Type

6.5.1 Europe Metabolic Syndrome Market, By Molecule Type Overview

6.5.2 Europe Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)

6.5.3 Europe Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)

6.5.4 Europe Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)

6.5.5 Europe Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)

6.6 Europe Metabolic Syndrome Market Segmentation: By Route of Administration

6.6.1 Europe Metabolic Syndrome Market, By Route of Administration Overview

6.6.2 Europe Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

6.6.3 Europe Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)

6.6.4 Europe Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

6.7 Europe Metabolic Syndrome Market Segmentation: By Country

6.7.1 France Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.1.1 France Metabolic Syndrome Market, By Indication

6.7.1.2 France Metabolic Syndrome Market, By Molecule Type

6.7.1.3 France Metabolic Syndrome Market, By Route of Administration

6.7.2 United Kingdom Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.2.1 United Kingdom Metabolic Syndrome Market, By Indication

6.7.2.2 United Kingdom Metabolic Syndrome Market, By Molecule Type

6.7.2.3 United Kingdom Metabolic Syndrome Market, By Route of Administration

6.7.3 Italy Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.3.1 Italy Metabolic Syndrome Market, By Indication

6.7.3.2 Italy Metabolic Syndrome Market, By Molecule Type

6.7.3.3 Italy Metabolic Syndrome Market, By Route of Administration

6.7.4 Spain Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.4.1 Spain Metabolic Syndrome Market, By Indication

6.7.4.2 Spain Metabolic Syndrome Market, By Molecule Type

6.7.4.3 Spain Metabolic Syndrome Market, By Route of Administration

6.7.5 Germany Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.5.1 Germany Metabolic Syndrome Market, By Indication

6.7.5.2 Germany Metabolic Syndrome Market, By Molecule Type

6.7.5.3 Germany Metabolic Syndrome Market, By Route of Administration

6.7.6 Rest of Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.6.1 Rest of Europe Metabolic Syndrome Market, By Indication

6.7.6.2 Rest of Europe Metabolic Syndrome Market, By Molecule Type

6.7.6.3 Rest of Europe Metabolic Syndrome Market, By Route of Administration

7. Asia-Pacific Metabolic Syndrome Market: Historic and Forecast (2018-2028)

7.1 Asia-Pacific Metabolic Syndrome Market: Snapshot

7.2 Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.3 Asia-Pacific Metabolic Syndrome Market: Key Factors

7.4 Asia-Pacific Metabolic Syndrome Market Segmentation: By Indication

7.4.1 Asia-Pacific Metabolic Syndrome Market, By Indication Overview

7.4.2 Asia-Pacific Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

7.4.3 Asia-Pacific Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)

7.4.4 Asia-Pacific Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

7.4.5 Asia-Pacific Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)

7.4.6 Asia-Pacific Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)

7.5 Asia-Pacific Metabolic Syndrome Market Segmentation: By Molecule Type

7.5.1 Asia-Pacific Metabolic Syndrome Market, By Molecule Type Overview

7.5.2 Asia-Pacific Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)

7.5.3 Asia-Pacific Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)

7.5.4 Asia-Pacific Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)

7.5.5 Asia-Pacific Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)

7.6 Asia-Pacific Metabolic Syndrome Market Segmentation: By Route of Administration

7.6.1 Asia-Pacific Metabolic Syndrome Market, By Route of Administration Overview

7.6.2 Asia-Pacific Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

7.6.3 Asia-Pacific Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)

7.6.4 Asia-Pacific Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

7.7 Asia-Pacific Metabolic Syndrome Market Segmentation: By Country

7.7.1 China Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.1.1 China Metabolic Syndrome Market, By Indication

7.7.1.2 China Metabolic Syndrome Market, By Molecule Type

7.7.1.3 China Metabolic Syndrome Market, By Route of Administration

7.7.2 Japan Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.2.1 Japan Metabolic Syndrome Market, By Indication

7.7.2.2 Japan Metabolic Syndrome Market, By Molecule Type

7.7.2.3 Japan Metabolic Syndrome Market, By Route of Administration

7.7.3 India Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.3.1 India Metabolic Syndrome Market, By Indication

7.7.3.2 India Metabolic Syndrome Market, By Molecule Type

7.7.3.3 India Metabolic Syndrome Market, By Route of Administration

7.7.4 Rest of Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.4.1 Rest of Asia-Pacific Metabolic Syndrome Market, By Indication

7.7.4.2 Rest of Asia-Pacific Metabolic Syndrome Market, By Molecule Type

7.7.4.3 Rest of Asia-Pacific Metabolic Syndrome Market, By Route of Administration

8. Middle-East & Africa Metabolic Syndrome Market: Historic and Forecast (2018-2028)

8.1 Middle-East & Africa Metabolic Syndrome Market: Snapshot

8.2 Middle-East & Africa Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

8.3 Middle-East & Africa Metabolic Syndrome Market: Key Factors

8.4 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication

8.4.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview

8.4.2 Middle-East & Africa Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

8.4.3 Middle-East & Africa Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)

8.4.4 Middle-East & Africa Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)

8.4.5 Middle-East & Africa Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)

8.4.6 Middle-East & Africa Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)

8.5 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication

8.5.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview

8.5.2 Middle-East & Africa Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)

8.5.3 Middle-East & Africa Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)

8.5.4 Middle-East & Africa Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)

8.5.5 Middle-East & Africa Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)

8.6 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Route of Administration

8.6.1 Middle-East & Africa Metabolic Syndrome Market, By Route of Administration Overview

8.6.2 Middle-East & Africa Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

8.6.3 Middle-East & Africa Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)

8.6.4 Middle-East & Africa Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on the Global Metabolic Syndrome Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Macro-Economic Factor Assessment

10.3 Porter’s Five Forces Model

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Position Matrix

11.3 Market Share Analysis of Metabolic Syndrome Market

11.4 Company Profiles

11.4.1 Novo Nordisk

11.4.2 Eli Lilly and Company

11.4.3 Takeda Pharmaceutical

11.4.4 Sanofi

11.4.5 AstraZeneca

11.4.6 Amgen

11.4.7 Merck Co., Inc.

11.4.8 Johnson & Johnson

11.4.9 Pfizer

11.4.10 Abbott

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Metabolic Syndrome Market (2023 Edition)” which provides a complete analysis of the global Metabolic Syndrome industry in terms of market segmentation By Indication (Insulin Resistance Syndrome, Hypercholesterolemia, Obesity Syndrome, Nonalcoholic steatohepatitis, Other Indications), By Molecule Type (Small Molecule, Protein, RNA/DNA, Other Molecules) and By Route of Administration (Oral, Subcutaneous, Other ROA) for the historical period of 2018-2022, the estimated year 2023 and the forecast period of 2024-2028.

The research study is global in nature and covers a detailed analysis of the market in the Americas (U.S., Canada, Rest of Americas), Europe (France, U.K, Italy, Spain, Germany, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), and the Middle East and Africa. Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, demand for future forecast, and so on.

The research study also assesses market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Metabolic Syndrome Market is expected to generate USD 28.9 billion by the end of 2028, up from USD 22.5 billion in 2021. Metabolic syndrome is a complicated disorder characterized by a group of linked metabolic abnormalities that raise the risk of cardiovascular disease, type 2 diabetes, and other major health problems. It is a global health issue with significant public health implications. Central obesity, high blood pressure, dyslipidemia (abnormal lipid profile), and reduced metabolism of glucose are important components of metabolic syndrome. During the forecast period, 2024-2028, the Global Metabolic Syndrome market is expected to expand at a CAGR of 46.30%.

In addition, as the healthcare sector moves toward a more preventive and customized approach, there is a greater emphasis on early detection and management to reduce the risk of metabolic syndrome-related challenges. This pattern is likely to fuel demand for diagnostic tests, treatment options, and digital health solutions.

Companies are working on creating novel drugs that address many aspects of metabolic syndrome at the same time. This strategy seeks to enhance patient outcomes while reducing the need for multiple drugs. Furthermore, technological advances such as wearable gadgets and mobile applications have evolved to assist individuals in monitoring their health metrics and successfully managing their condition.

Among the Indication type, Insulin Resistance Syndrome holds the maximum share in the market. The global market for therapeutics of Insulin resistance Metabolic Syndrome is expected to grow in the coming years, driven by the increasing prevalence of Diabetes.

This study also provides a competitive landscape of the industry and profiles leading players in the Global Metabolic Syndrome Market including Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceutical, Sanofi, AstraZeneca, Amgen, Merck Co., Inc., Johnson & Johnson, Pfizer, and Abbott. The company profiling includes critical information such as a business overview, Drug Molecule type and other products, key financials, and recent events and developments. Overall, the report provides a detailed overview of the Global Metabolic Syndrome Market, which will assist industry consultants, equipment manufacturers, existing players looking for expansion opportunities, new players looking for opportunities, and other stakeholders in aligning their market-centric strategies with current and expected future trends.

Scope of the Report:

• The report analyses the Metabolic Syndrome Market by Value (USD Million).

• The report presents the analysis of Metabolic Syndrome market for the historical period of 2018-2022, the estimated year 2023 and the forecast period of 2024-2028.

• The report analyses the Metabolic Syndrome Market by Indication (Insulin Resistance Syndrome, Hypercholesterolemia, Obesity Syndrome, Nonalcoholic steatohepatitis, Other Indications).

• The report analyses the Metabolic Syndrome Market by Molecule Type (Small Molecule, Protein, RNA/DNA, Other Molecules).

• The report analyses the Metabolic Syndrome Market by Route of Administration (Oral, Subcutaneous, Other ROA).

• The Global Metabolic Syndrome Market has been analysed by countries including the United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, India and Japan.

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by Metabolic Syndrome Type, by Metabolic Syndrome Form, and by Sales Channel.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceutical, Sanofi, AstraZeneca, Amgen,Merck Co., Inc., Johnson & Johnson, Pfizer, and Abbott.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（obesity）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

メタボリックシンドロームの世界市場（2023年版）：適応症別（NASH、IRS、高コレステロール血症、肥満症候群、その他）、分子タイプ別、投与経路別、地域別、国別の分析：市場インサイトと予測（2018年～2028年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（obesity）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?